Spots Global Cancer Trial Database for Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Official Title: Toripalimab Combined With Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma
Study ID: NCT04405622
Interventions
Study Description
Brief Summary: This is an open-label, single center, pilot trial to evaluate the safety and efficacy of toripalimab and gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ming-Yuan Chen, Guangzhou, Guangdong, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
